Filtered By:
Drug: Lipitor
Education: Study

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 785 results found since Jan 2013.

Cholesterol – the super-stealthy invisible illness
Sourced from The Hysterectomy Association: Hysterectomy Association - Hysterectomy Association - hysterectomy, menopause and hormone replacement therapy (hrt) information and support for women. As far as invisible illnesses go, they don’t come much stealthier than high cholesterol. It’s easily ignored because it builds up gradually, often showing no symptoms whatsoever. A person with high or increasing cholesterol levels will most likely feel perfectly healthy. It’s a scary though that the first sign of high cholesterol may be a heart attack or stroke – and could even prove fatal! Fortunately, medical professionals...
Source: The Hysterectomy Association - March 26, 2015 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Health Conditions cholesterol invisible illness Source Type: news

Differential Effects of Strong and Regular Statins on the Clinical Outcome of Patients With Chronic Kidney Disease Following Coronary Stent Implantation.
Conclusions:In patients with mild-to-moderate CKD, only strong statins were associated with lower risk compared with no statin, but regular statins were not. It is possible that taking a strong statin from the early stage of CKD is useful for suppression of cardiovascular events. PMID: 25739954 [PubMed - as supplied by publisher]
Source: Circulation Journal - February 24, 2015 Category: Cardiology Authors: Ishii M, Hokimoto S, Akasaka T, Fujimoto K, Miyao Y, Kaikita K, Oshima S, Nakao K, Shimomura H, Tsunoda R, Hirose T, Kajiwara I, Matsumura T, Nakamura N, Yamamoto N, Koide S, Oka H, Morikami Y, Sakaino N, Matsui K, Ogawa H, on behalf of the Kumamoto Inter Tags: Circ J Source Type: research

Why You Should Avoid Statins
At my anti-aging clinic, I continue to wage war against what I call the “medical-industrial complex.” And I do it for one reason only – I care more about my patients than I do about profits. Big Pharma clearly takes the opposite view. And now it seems these pharmaceutical behemoths won’t be happy until every man, woman and child is popping anti-cholesterol pills. Researchers at Duke University recently issued a report recommending that even children and people as young as 30 should be on statins, if they have just slightly elevated cholesterol levels.1 And why wouldn’t researchers at Duke recommen...
Source: Al Sears, MD Natural Remedies - February 3, 2015 Category: Complementary Medicine Authors: Dr. Al Sears Tags: Heart Health Source Type: news

Effect of 20 mg/day Atorvastatin: Recurrent Stroke Survey in Chinese Ischemic Stroke Patients with Prior Intracranial Hemorrhage.
CONCLUSIONS: Medication with 20 mg/day atorvastatin may be beneficial in reducing ischemic stroke recurrence in ischemic stroke patients with a history of ICH and is not associated with an increased risk of ICH recurrence. PMID: 23894236 [PubMed]
Source: Journal of Clinical Neurology - December 2, 2014 Category: Neurology Tags: J Clin Neurol Source Type: research

Assessment of Lipophilic vs. Hydrophilic Statin Therapy in Acute Myocardial Infarction.
Conclusions:On 2-year comparison of hydrophilic and lipophilic statins there was no significant difference in prevention of secondary cardiovascular outcome. PMID: 25392071 [PubMed - as supplied by publisher]
Source: Circulation Journal - November 12, 2014 Category: Cardiology Authors: Izawa A, Kashima Y, Miura T, Ebisawa S, Kitabayashi H, Yamamoto H, Sakurai S, Kagoshima M, Tomita T, Miyashita Y, Koyama J, Ikeda U Tags: Circ J Source Type: research

Atorvastatin Treatment and Carotid Plaque Morphology in First-ever Atherosclerotic Transient Ischemic Attack/Stroke: A Case–Control Study
A relationship between echolucency of carotid plaques and the consequent risk of ipsilateral ischemic stroke has been observed. An aggressive lipid-lowering therapy may increase the echogenicity of carotid plaque in patients with elevated low-density lipoprotein cholesterol levels. The aim of this study is to prospectively evaluate the long-term effect of high-dose atorvastatin on carotid plaque morphology in patients with first-ever transient ischemic attack or stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - October 21, 2014 Category: Neurology Authors: Pasquale Marchione, Claudio Vento, Manuela Morreale, Chiara Izzo, Andrea Maugeri, Federica Manuppella, Tommaso Romeo, Patrizia Giacomini Source Type: research

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
Publication date: Available online 7 August 2014 Source:American Heart Journal Author(s): Gregory G. Schwartz , Laurence Bessac , Lisa G. Berdan , Deepak L. Bhatt , Vera Bittner , Rafael Diaz , Shaun G. Goodman , Corinne Hanotin , Robert A. Harrington , J. Wouter Jukema , Kenneth W. Mahaffey , Angèle Moryusef , Robert Pordy , Matthew T. Roe , Tyrus Rorick , William J. Sasiela , Cheerag Shirodaria , Michael Szarek , Jean-François Tamby , Pierluigi Tricoci , Harvey White , Andreas Zeiher , Philippe Gabriel Steg Following acute coronary syndrome (ACS), the risk for future cardiovascular events is high and is related to le...
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research

Effect of High-Dose Atorvastatin on Renal Function in Subjects With Stroke or Transient Ischemic Attack in the SPARCL Trial Clinical Sciences
Conclusions— This post hoc analysis suggests that atorvastatin treatment may improve renal function in patients with prior stroke or transient ischemic attack with and without chronic kidney disease, and that atorvastatin treatment may prevent eGFR decline in patients with stroke and diabetes mellitus. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00147602.
Source: Stroke - September 22, 2014 Category: Neurology Authors: Amarenco, P., Callahan, A., Campese, V. M., Goldstein, L. B., Hennerici, M. G., Messig, M., Sillesen, H., Welch, K. M. A., Wilson, D. J., Zivin, J. A. Tags: Lipids, Secondary prevention, Cerebrovascular disease/stroke Clinical Sciences Source Type: research

Glun2b N‐methyl‐D‐aspartic acid receptor subunit mediates atorvastatin‐Induced neuroprotection after focal cerebral ischemia
This study evaluates whether atorvastatin (ATV) treatment affects the GluN1 and GluN2B subunits of the N‐methyl‐D‐aspartic acid receptor in the somatosensory cerebral cortex at short and long periods following ischemia. Sham and ischemic male Wistar rats received 10 mg/kg of ATV or placebo by gavage every 24 hr for 3 consecutive days. The first dose was administered 6 hr after ischemia–reperfusion or the sham operation. ATV treatment resulted in faster recovery of neurological scores than placebo, prevented the appearance of pyknotic neurons, and restored microtubule‐associated protein 2 and neuronal nuclei stain...
Source: Journal of Neuroscience Research - June 17, 2014 Category: Neuroscience Authors: Johanna Andrea Gutierrez‐Vargas, Juan Ignacio Muñoz‐Manco, Luis Miguel Garcia‐Segura, Gloria Patricia Cardona‐Gómez Tags: Research Article Source Type: research

Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke
Conclusions: Pre-treatment with PPARalpha agonist or atorvastatin show potential neuroprotective effects by inhibiting the PDI overexpression in conjunction with the preservation of other neuronal markers, several of which are associated with the regulation of protein homeostasis, signal transduction and maintenance of synaptic plasticity. This proteomic study therefore suggests that neuroprotective effect of PPARalpha agonists supposes the preservation of the expression of several proteins essential for the maintenance of protein homeostasis not necessarily directly linked to PPARalpha known-regulated targets.
Source: Proteome Science - May 6, 2014 Category: Bioinformatics Authors: Patrick GeléValérie VingtdeuxCamille PoteyHervé DrobecqAntoine GhestemPatricia MelnykLuc BuéeNicolas SergeantRégis Bordet Source Type: research

The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial
Abstract: Background: Current guidelines recommend intensive low-density lipoprotein (LDL) cholesterol lowering with statins, with a target of 70mg/dL (1.81mmol/L) LDL cholesterol for those with a very high risk of coronary artery events. However, there is no multicenter study assessing the effect of intensive lipid-lowering therapy with statins on acute coronary syndrome (ACS) in a Chinese population with low baseline LDL cholesterol levels.Methods and results: Patients (n=1355) with ACS were treated with a moderate dose of statin (atorvastatin 10 mg/d, or equivalent dose of other statins, n=675) or with an intensive dose...
Source: Atherosclerosis - March 20, 2014 Category: Cardiology Authors: Shui-ping Zhao, Bi-lian Yu, Dao-quan Peng, Yong Huo Tags: Clinical & Population Research – Intervention Source Type: research

Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events.
CONCLUSIONS: This study found that switching from rosuvastatin to atorvastatin led to fewer patients attaining LDL-C goal and a greater risk for MACE. PMID: 24417785 [PubMed - in process]
Source: Clinical Therapeutics - January 1, 2014 Category: Drugs & Pharmacology Authors: Folse H, Sternhufvud C, Andy Schuetz C, Rengarajan B, Gandhi S Tags: Clin Ther Source Type: research

Tissue kallikrein preventing the restenosis after stenting of symptomatic MCA atherosclerotic stenosis (KPRASS)
ConclusionAs our pilot study, tissue kallikrein would be expected to prevent the long‐term in‐stent restenosis after stenting of the symptomatic middle cerebral artery dramatically.
Source: International Journal of Stroke - December 21, 2013 Category: Neurology Authors: Wenya Lan, Fang Yang, Ling Liu, Qin Yin, Min Li, Zhuangli Li, Hongfei Sang, Gelin Xu, Minmin Ma, Zhizhong Zhang, Zhenguo Liu, Xinfeng Liu, Renliang Zhang Tags: Protocols Source Type: research

Anti-inflammatory and anti-thrombogenic effects of atorvastatin in acute ischemic stroke
(Neural Regeneration Research) A recent study by Lianqiu Min and colleagues from Liaoning Medical University observed the effects of atorvastatin treatment in 89 patients from northeastern China with acute ischemic stroke caused by intracranial large-artery atherosclerosis by measuring changes in the levels of markers of inflammation, thrombogenesis, and hyperlipidemia.
Source: EurekAlert! - Medicine and Health - September 10, 2013 Category: Global & Universal Source Type: news

Ultra-Sensitive Molecular MRI of Vascular Cell Adhesion Molecule-1 Reveals a Dynamic Inflammatory Penumbra After Strokes Basic Sciences
Conclusions— MPIOs-αVCAM-1–enhanced imaging seems to be promising in the detection of individuals presenting with severe cerebrovascular responses after stroke, which could therefore benefit from anti-inflammatory treatments.
Source: Stroke - June 24, 2013 Category: Neurology Authors: Gauberti, M., Montagne, A., Marcos-Contreras, O. A., Le Behot, A., Maubert, E., Vivien, D. Tags: Computerized tomography and Magnetic Resonance Imaging, Thrombolysis, Endothelium/vascular type/nitric oxide Basic Sciences Source Type: research